MitoReID identifies epicatechin as a cyclooxygenase-2 inhibitor
A deep-learning system called MitoReID classified drug mechanisms from time-resolved mitochondrial morphology and membrane-potential images. Among its natural-compound predictions, it nominated epicatechin as a COX-2 inhibitor; the authors report in-vitro follow-up including COX-2 activity, cellular thermal-shift and surface-plasmon-resonance assays. This is a target-mechanism finding, not evidence of clinical efficacy.
Technology: MitoReID, deep-learning re-identification model using an Inflated 3D ResNet backbone on temporal mitochondrial images
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Among its natural-compound predictions, it nominated epicatechin as a COX-2 inhibitor; the authors report in-vitro follow-up including COX-2 activity, cellular thermal-shift and surface-plasmon-resonance assays.
- Still unknown: Evidence is biochemical/in-vitro and does not establish therapeutic efficacy or safety. MitoReID's six unseen-drug mechanism predictions are a separate task; the epicatechin COX-2 result is the specific new mechanistic finding recorded here. Full publisher page was cookie-blocked, but the primary PubMed record and publisher-indexed article text/extended-data caption were read.
- AI role: Ranked mechanisms of action for compounds by matching learned time-dependent mitochondrial phenotypes against reference drugs; the model nominated COX-2 inhibition for epicatechin, which was tested in vitro.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39169261/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 63 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.